tirzepatide surmount 1 SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 👀 📉Sustained weight loss of 22.9% or an average 54lbs over 3 years 🔽94% reduction in risk of progression to diabetes. Number Tirzepatide for Obesity Treatment and

In direct terms: semaglutide reduces energy intake through appetite suppression

Most providers require an initial consultation to confirm eligibility

You should refrain from taking semaglutide if you: Are pregnant or breastfeeding Have kidney disease Have a history of certain diseases, like thyroid cancer If youre unsure whether semaglutide is right for you, talk with your provider about your concerns

If youre still deciding how to begin treatment, the free assessment quiz can help you take the next step

We tested human CRC cell models SW480 (a KRAS mutant, TP53 mutant MSS line

Sometimes 40 to 60 percent less than before